Related references
Note: Only part of the references are listed.Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence
Sonia Khemais-Benkhiat et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
Giuseppe Cianciolo et al.
MOLECULES (2020)
Glucose transport in lymphocytes
Florian Lang et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
Jun Zhou et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Cytokines and transcription factors in the differentiation of CD4+ T helper cell subsets and induction of tissue inflammation and autoimmunity
Mathias Pawlak et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
Evaluation of Interleukin-23 and JAKs/STATs/SOCSs/ROR-γt Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin
Mahsa Rezaeepoor et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2020)
Effects of sitagliptin and vitamin D3 on T helper cell transcription factors and cytokine production in clinical subgroups of type 2 diabetes mellitus: highlights upregulation of FOXP3 and IL-37
Zahra Telikani et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2019)
Anti-Inflammatory Effect of Combined Sitagliptin and Vitamin D3 on Cytokines Profile in Patients with Type 2 Diabetes Mellitus
Shiva Borzouei et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
The increased T helper cells proliferation and inflammatory responses in patients with type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro
Elham Mahabadi-Ashtiyani et al.
INFLAMMATION RESEARCH (2019)
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
David A. Hess et al.
CELL METABOLISM (2019)
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Jan Pennig et al.
SCIENTIFIC REPORTS (2019)
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
Francesca Iannantuoni et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Expression of CD4+CD25+Foxp3+Regulatory T Cells, Interleukin 10 and Transforming Growth Factor in Newly Diagnosed Type 2 Diabetic Patients
Ning Yuan et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2018)
The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus
Adel Abdel-Moneim et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients
Mei Wang et al.
CLINICAL IMMUNOLOGY (2018)
Decreased regulatory function of CD4+CD25+CD45RA+ T cells and impaired IL-2 signalling pathway in patients with type 2 diabetes mellitus
Vida Sheikh et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2018)
Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
Sachiko Hattori
DIABETOLOGY & METABOLIC SYNDROME (2018)
Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus
Tong Zhou et al.
JOURNAL OF DIABETES RESEARCH (2018)
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Ji Hye Han et al.
DIABETOLOGIA (2017)
Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation
Chang Xia et al.
JOURNAL OF DIABETES RESEARCH (2017)
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Itay Raphael et al.
CYTOKINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
T-Cell Profile in Adipose Tissue Is Associated With Insulin Resistance and Systemic Inflammation in Humans
Tracey McLaughlin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Inflammatory Cytokines and the Risk of Cardiovascular Complications in Type 2 Diabetes
Fadia Mahmoud et al.
DISEASE MARKERS (2013)
Decreased interferon-alpha and interferon-beta production in obesity and expression of suppressor of cytokine signaling
Eli Teran-Cabanillas et al.
NUTRITION (2013)
Regulatory T Cells: Mechanisms of Differentiation and Function
Steven Z. Josefowicz et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance
Shawn Winer et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications
Chun Zeng et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Elevated Proinflammatory Cytokine Production by a Skewed T Cell Compartment Requires Monocytes and Promotes Inflammation in Type 2 Diabetes
Madhumita Jagannathan-Bogdan et al.
JOURNAL OF IMMUNOLOGY (2011)
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function
Douglas C. Palmer et al.
TRENDS IN IMMUNOLOGY (2009)
Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival
Nancie J. MacIver et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Share Paper
